Differential effects of estradiol and its analogs on cyclin D1 and CDK4 expression in estrogen receptor positive MCF-7 and estrogen receptor-transfected MCF-10AEwt5 cells

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1025-1033

  Hong, Jiantao ^a   Shah, Neha N ^a   Thomas, T J ^a   Gallo, Michael A ^a   Yurkow, Edward J ^b   Thomas, Thresia ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

CDK4; Cyclin D1; Estradiol; MCF 7 cells

Indexed keywords

2 HYDROXYESTRATRIEN 17BETA OL; 3 HYDROXYESTRATRIENE; 4 HYDROXYESTRATRIEN 17BETA OL; CYCLIN D1; CYCLIN DEPENDENT KINASE; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTRATRIEN 17BETA OL; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; ESTRADIOL; FEMALE; HUMANS; KINETICS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031854959     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1025     Document Type: Article

References (63)

1. Henderson BE, Ross RK and Pike MC: Hormonal chemoprevention of cancer in women. Science 259: 633-638, 1993.
2. Clarke R, Dickson RB and Lippman ME: Hormonal aspects of breast cancer. Crit Rev Oncol Hematol 12: 1-23, 1992.
3. Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S and Franceschi S: Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 90: 453-456, 1997.
4. Cahn MD, Tran T, Theur CP and Butler JA: Hormone replacement therapy and the risk of breast lesions that predispose to cancer. Am Surg 63: 858-860, 1997.
5. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kasterner P, Chambon P and Evans RM: The nuclear receptor superfamily. Cell 83: 835-839, 1995.
6. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takmoto GS and Tung L: Nuclear receptor activators and corepressors. Mol Endocrinol 10: 1167-1177, 1996.
7. Katzenellenbogen JA, O'Malley BW and Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology; interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10: 119-131, 1996.
8. Kuiper G, Carlsson B, Grandien K, Enmark E, Hagglad J, Nilsson S and Gustafsson J-A: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138: 863-870, 1997.
9. Van der Burg B, van Selm-Miltenburg AJ, De Laat SW and van Zoelen EJ: Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 64: 223-228, 1989.
10. Weisz A, Cicatiello L, Persico E, Scalona M and Bresciani F: Estrogen stimulates transcription of c-jun protooncogene. Mol Endocrinol 4: 1041-1050, 1990.
11. Kasid A and Lippman ME: Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem 27: 465-470, 1987.
12. Thomas T and Thomas TJ: Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat 29: 189-201, 1993.
13. Thomas T, Faaland CA, Adhikarakunnathu S and Thomas TJ: Structure-activity correlations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 39: 293-306, 1996.
14. Wilken NRC, Prall OWJ, Musgrove EA and Sutherland RL: Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3: 849-854, 1997.
15. Foster JS and Wimalasena J: Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10: 488-498, 1996.
16. Norbury C and Nurse P: Animal cell cycles and their control. Annu Rev Biochem 61: 441-470, 1992.
17. Murray A and Hunt T: The cell cycle. Oxford University Press, Oxford, 1993.
18. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
19. Collins K, Jacks T and Pavletich NP: The cell cycle and cancer. Proc Natl Acad Sci USA 94: 2776-2778, 1997.
20. Lukas J, Bartkova J and Bartek J: Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 check-point. Mol Cell Biol 16: 6917-6925, 1996.
21. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV: Mammary hyperplasia in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671, 1994.
22. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
23. Fant V, Stamp G, Andrews A, Rosewell I and Dickson C: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9: 2364-2372, 1995.
24. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894, 1997.
25. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F and Weisz A: 17β-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(l)-arrested human breast cancer cells. Oncogene 12: 2315-2324, 1996.
26. Masciullo V, Scambia G, Marone M, Giannitelli C, Ferrandina G, Bellacosa A, Benedetti Panici P and Mancuso S: Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 74: 390-395, 1997.
27. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S and Webster KR: Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 272: 18869-18874, 1997.
28. Geng Y and Weinberg RA: Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 90: 10315-10319, 1993.
29. Haas K, Staller P, Geisen C, Bartek J, Eilers M and Moroy T: Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16/ INK4A as upstream regulators of Myc. Oncogene 15: 179-192, 1997.
30. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG and Hayward NK: CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57: 4868-4875, 1997.
31. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Muller-Hermelink HK, Bentz M, Hiddemann W and Dohner H: Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 57: 4608-4614, 1997.
32. Harrison PT, Holmes P and Humfrey CD: Reproductive health in humans and wildlife: are adverse trends associated with environmental chemical exposure? Sci Total Environ 205: 97-106, 1997.
33. Danzo BJ: Environmental xenobiotics may disrupt normal endocrine function by interfering with the binding of physiological ligands to steroid receptors and binding proteins. Environ Health Perspect 105: 294-301, 1997.
34. Arnold SF, Vonier PM, Collins BM, Klotz DM, Guillette LJ Jr and McLachlan JA: In vitro synergistic interaction of alligator and human estrogen receptors with combinations of environmental chemicals. Environ Health Perspect 105 (Suppl 3): 615-618, 1997.
35. Ramamoorthy K, Wang F, Chen IC, Safe S, Morris JD, McDonnell DP, Gaido KW, Bocchinfuso WP and Korach KS: Potency of combined estrogenic pesticides. Science 275: 405-406, 1996.
36. Davis DL, Bradlow HL, Wolff MS, Woodruff T, Hoel G and Anton-Culver H: Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Health Perspect 101: 372-377, 1993.
37. Wolff MS, Toniolo PG, Lee EW and Dubin RN: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85: 648-652, 1993.
38. Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman J and Orentreich N: Breast cancer and serum organochlorines: a prospective study among White, Black, and Asian women. J Natl Cancer Inst 86: 589-599, 1994.
39. Van der Kurr JA, Wiese T and Brooks SC: Influence of estrogen structure on nuclear binding and progesterone receptor induction by the receptor complex. Biochemistry 32: 7002-7008, 1993.
40. Van der Kuur JA, Hafner MS, Christman JK and Brooks SC: Effects of estradiol-17β analogues on activation of estrogen response element regulated chloramphenicol acetyltransferase expression. Biochemistry 32: 7016-7021, 1993.
41. Pilat MJ, Hafner MS, Kral LG and Brooks SC: Differential induction of pS2 and cathepsin D mRNAs by structurally altered estrogens. Biochemistry 32: 7009-7015, 1993.
42. Thomas T, Trend B, Butterfield JR, Jänne OA and Kiang DT: Regulation of ornithine decarboxylase gene expression in MCF-7 breast cancer cells by antiestrogens. Cancer Res 49: 5852-5857, 1989.
43. Thomas TJ, Faaland CA, Adhikarakunnathu S, Watkins L and Thomas T: Induction of p21(CIP1/WAF1/SID1) by estradiol in a breast epithelial cell line transfected with the recombinant estrogen receptor gene: a possible mechanism for a negative regulatory role of estradiol. Breast Cancer Res Treat 47: 181-193, 1998.
44. Thomas T and Thomas TJ: Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Res 54: 1077-1084, 1994.
45. Thomas TJ, Shah N, Faaland CA, Gallo MA, Yurkow E, Satyaswaroop PC and Thomas T: Anti-tumor effects of a bis(benzyl)spermine analog on MCF-7 breast cancer cells in culture and in nude mice xenografts. Oncol Rep 4: 5-13, 1997.
46. Thomas T and Klang DT: Ribonuclease-induced transformation of progesterone receptor from rabbit uterus. J Steroid Biochem 24: 505-511, 1986.
47. Thomas T and Leung BS: Characterization of nuclear estradiol receptors released by micrococcal nuclease and DNAse I. J Steroid Biochem 21: 35-42, 1984.
48. Thomas T and Kiang DT: Structural alterations and stabilization of rabbit uterine estrogen receptors by natural polyamines. Cancer Res 47: 1799-1804, 1987.
49. Zajchowski DA, Sager R and Webster L: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 53: 5004-5011, 1993.
50. Jiang S-Y and Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complimentary DMAs for estrogen receptor. J Natl Cancer Inst 84: 580-591, 1992.
51. Musgrove EA, Lee CS, Buckley MF and Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91: 8022-8026, 1994.
52. Nielsen DA and Shapiro DJ: Estradiol and estrogen receptor-dependent stabilization of a minivitellogenin mRNA lacking 5,100 nucleotides of coding sequence. Mol Cell Biol 10: 371-376, 1990.
53. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG and Dorsa DM: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138: 4030-4033, 1997.
54. Garcia M, Derocq D, Freiss G and Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89: 11538-11542, 1992.
55. Kushner PJ, Hort E, Shine J, Baxter JD and Greene GL: Construction of cell lines that express high levels of the human estrogen receptor that are killed by estrogens. Mol Endocrinol 4: 1465-1473, 1990.
56. Wang W, Smith R III, Burghardt R and Safe SH: 17β-estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol Cell Endocrinol 133: 49-62, 1997.
57. Schwartz JA and Skafar DF: Ligand-mediated modulation of estrogen receptor conformation by estradiol analogs. Biochemistry 32: 10109-10115, 1993.
58. Christman JK, Nehls S, Polin L and Brooks SC: Relationship between estrogen structure and conformational changes in estrogen receptor/DNA complexes. J Steroid Biochem Mol Biol 54: 201-210, 1995.
59. Anstead GM, Carlson KE and Katzenellenbogen JA: The estradiol pharmacophore ligand structure-estrogen receptor binding affinity relationships and a model for receptor binding site. Steroids 62: 268-303, 1997.
60. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA and Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997.
61. Duax WL, Griffin JF, Weeks CM and Wawrzak Z: The mechanism of action of steroid antagonists: insights from crystallographic studies. J Steroid Biochem 31: 481-492, 1988.
62. Wiese TE, Polin LA, Palomino E and Brooks SC: Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogue of estradiol-17β: a 3D QSAR study. J Med Chem 40: 3659-3669, 1997.
63. Melmed M, Castano E, Notides AC and Sason S: Molecular and kinetic basis form the mixed agonist/antagonist activity of estradiol. Mol Endocrinol 11: 1868-1876, 1997.